Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy
Status:
Recruiting
Trial end date:
2025-01-16
Target enrollment:
Participant gender:
Summary
This is a phase 1, multi-center, double-blind, placebo-controlled, multiple dose escalation
study with NIO752 in progressive supranuclear palsy (PSP) participants.